APYX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APYX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Apyx Medical's Enterprise Value is $50.14 Mil. Apyx Medical's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.90 Mil. Therefore, Apyx Medical's EV-to-EBIT ratio for today is -2.19.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Apyx Medical's Enterprise Value is $50.14 Mil. Apyx Medical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-22.30 Mil. Therefore, Apyx Medical's EV-to-EBITDA ratio for today is -2.25.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Apyx Medical's Enterprise Value is $50.14 Mil. Apyx Medical's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $48.54 Mil. Therefore, Apyx Medical's EV-to-Revenue ratio for today is 1.03.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Apyx Medical's Enterprise Value is $50.14 Mil. Apyx Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-17.89 Mil. Therefore, Apyx Medical's EV-to-FCF ratio for today is -2.80.
The historical data trend for Apyx Medical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apyx Medical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial |
![]() |
![]() |
231.40 | 205.78 | 410.88 | 71.77 | 85.84 |
Apyx Medical Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Enterprise Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
103.35 | 85.84 | 48.67 | 52.62 | 53.95 |
For the Medical Devices subindustry, Apyx Medical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Apyx Medical's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Apyx Medical's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 90.76728 | + | 0 | + | 38.134 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.367 | + | 0.221 | - | 43.652 |
= | 85.84 |
Apyx Medical's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as
Enterprise Value (Q: Sep. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 42.95856 | + | 0 | + | 38.497 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.35 | + | 0.156 | - | 28.013 |
= | 53.95 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apyx Medical (NAS:APYX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Apyx Medical's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 50.140 | / | -22.904 | |
= | -2.19 |
Apyx Medical's current Enterprise Value is $50.14 Mil.
Apyx Medical's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.90 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Apyx Medical's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 50.140 | / | -22.295 | |
= | -2.25 |
Apyx Medical's current Enterprise Value is $50.14 Mil.
Apyx Medical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.30 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Apyx Medical's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 50.140 | / | 48.542 | |
= | 1.03 |
Apyx Medical's current Enterprise Value is $50.14 Mil.
Apyx Medical's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.54 Mil.
4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.
Apyx Medical's EV-to-FCF for today is:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 50.140 | / | -17.892 | |
= | -2.80 |
Apyx Medical's current Enterprise Value is $50.14 Mil.
Apyx Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Apyx Medical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Todd Hornsby | officer: Executive Vice President | 14321 HAWTHORNE DR., CARMEL IN 46033 |
Goodwin Charles D. Ii | director, officer: Chief Executive Officer | 5115 ULMERTON ROAD, CLEARWATER FL 33760 |
Wendy Lauren Levine | director | 75 KENMARE STREET, APT. 2D, NEW YORK NY 10012 |
Minnie Baylor-henry | director | C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
Tara Semb | officer: Chief Financial Officer | 5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225 |
Craig A. Swandal | director | 5115 ULMERTON ROAD, CLEARWATER FL 33760 |
Michael Geraghty | director | 1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118 |
Lawrence Waldman | director | 5115 ULMERTON RD., CLEARWATER FL 33770 |
John C. Andres | director | 86 CAPRI LANE, CHATHAM MA 02633 |
Jay D. Ewers | officer: Chief Financial Officer | 4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577 |
J Robert Saron | director, officer: President | |
Robert Gershon | director, officer: Chief Executive Officer | 5115 ULMERTON ROAD, CLEARWATER FL 33760 |
Mccarthy John J. Iii | officer: Chief CommercializationOfficer | 23 RINALDO ROAD, NORTHPORT NY 11768 |
Scott Richard Davidson | director | C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830 |
Moshe Citronowicz | officer: Vice President of Operations |
From GuruFocus
By GuruFocus News • 11-08-2024
By GuruFocus Research • 03-22-2024
By GuruFocus News • 10-15-2024
By GuruFocus News • 11-09-2024
By Marketwired • 11-27-2024
By Business Wire • 05-09-2024
By PRNewswire • 06-26-2024
By GuruFocus News • 10-09-2024
By GuruFocus News • 11-07-2024
By Marketwired • 11-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.